Join our daily newsletter At The Bell to receive exclusive market insights
- Race Oncology (RAC) joins forces with the University of Wollongong (UOW) for a preclinical evaluation of new formulations of its Zantrene anti-cancer drug
- The collaboration provides Race with access to UOW’s lab and expertise to rapidly advance the development of its formulation, while at a lower cost and greater speed
- The strategic collaborative research agreement will see trials start immediately, with results due to be reported over the coming year
- Race Oncology is trading a slight 0.3 per cent higher at $3.29
Race Oncology (RAC) has joined forces with the University of Wollongong (UOW) for a preclinical evaluation of new formulations of Zantrene.
The strategic collaborative research agreement with UOW will provide Race with access to the lab, instrumental capabilities, and expertise to rapidly advance the development of its formulation at a lower cost and greater speed, while generating and capturing new patentable IP.
“This is an exciting and valuable collaboration for Race as we develop new Zantrene formulations and expand our pipeline,” Chief Scientific Officer Dr Daniel Tillett said.
Prior to the new collaboration, Race has been developing new formulations of Zantrene that offer the potential for long-acting peripheral IV administration in an outpatient setting.
Currently, Zantrene requires the use of a central venous catheter in a hospital setting to be administered to a patient. While this is a standard method for many chemotherapy drugs, the company said it believes longer-acting and more patient-friendly routes of administration are key to achieve the full market potential of Zantrene.
The company said additional programs have already identified several formulation approaches that could allow Zantrene to be delivered orally.
The new collaboration will start immediately, with results due to be reported over the coming year.
While the contract value is not material in dollar terms, Race Oncology said it will transform its research and development capability, so it can optimise and enhance Zantrene formulations and their utility in additional patient settings.
Race Oncology was trading a slight 0.3 per cent higher at $3.29 at 12:00 pm AEDT.
